×
About 49,772 results

ALLMedicine™ Renal Cell Carcinoma Center

Research & Reviews  23,633 results

Loss of 9p21 regulatory hub promotes kidney cancer progression by upregulating HOXB13.
https://doi.org/10.1158/1541-7786.MCR-20-0705
Molecular Cancer Research : MCR; Baietti MF, Zhao P et. al.

Feb 23rd, 2021 - Loss of chromosome 9p21 is observed in one-thirds of clear cell renal cell carcinoma (ccRCC) and associated with poorer patient survival. Unexpectedly, 9p21 loss-of-heterozygosity (LOH) does not lead to decreased expression of the 9p21 tumor suppr...

Two Cases of Sporadic Eosinophilic Solid and Cystic Renal Cell Carcinoma in Manitoba Po...
https://doi.org/10.1177/1066896921993229
International Journal of Surgical Pathology; Mohaghegh Poor SM, Mathur S et. al.

Feb 22nd, 2021 - Two sporadic cases of eosinophilic solid and cystic renal cell carcinoma (ESC RCC), at our institution, are presented in this study to contribute to the growing literature on this novel renal neoplasm. The first patient was a 38-year-old female wi...

Comorbidity and frailty assessment in renal cell carcinoma patients.
https://doi.org/10.1007/s00345-021-03632-6 10.3322/caac.21492 10.1007/s00345-010-0555-1 10.14740/wjon1279 10.1016/s0022-5347(17)68620-8 10.1016/j.eururo.2011.03.030 10.1016/j.annonc.2020.11.016 10.1016/S0140-6736(19)30723-8 10.1016/S1470-2045(20)30436-8 10.1016/j.annonc.2020.04.010 10.1056/NEJMoa1712126 10.1016/j.eururo.2019.02.011 10.1016/S0022-5347(05)00148-5 10.1097/01.ju.0000095475.12515.5e 10.1093/jnci/djj362 10.1002/cncr.25184 10.1002/cncr.26369 10.1016/j.eururo.2020.06.053 10.1016/j.juro.2014.03.038 10.1016/j.euf.2017.11.005 10.1016/j.juro.2009.12.101 10.2147/RRU.S220221 10.1016/j.eururo.2016.08.060 10.1016/j.eururo.2006.11.013 10.1016/j.urology.2014.01.050 10.1093/gerona/56.3.m146 10.1097/HJH.0000000000001286 10.1097/MOU.0000000000000454 10.1016/j.urolonc.2018.12.008 10.18632/oncotarget.3749 10.1002/ijc.28093 10.1016/j.eururo.2018.08.036 10.1016/1047-2797(91)90005-W 10.1093/annonc/mdr587 10.1200/JCO.2013.54.8347 10.1200/JCO.2013.51.1345 10.1371/journal.pone.0115060 10.1016/0021-9681(87)90171-8 10.1016/0895-4356(94)90129-5 10.1007/s00432-019-03042-7 10.1200/JCO.2009.22.4816 10.1016/j.cell.2010.01.025 10.2147/CMAR.S208839 10.1093/annonc/mdw328 10.1016/S1470-2045(16)30196-6 10.1016/j.urolonc.2007.10.017 10.1200/JCO.2019.37.15_suppl.4516 10.21037/atm.2019.01.08 10.1016/j.urolonc.2018.08.018 10.1016/j.eururo.2019.05.022 10.1016/j.eururo.2016.09.034 10.1016/j.eururo.2015.01.005 10.1016/annoncannonc325 10.1056/NEJMoa1816714 10.1056/NEJMoa1816047 10.1016/S0140-6736(19)30723-8 10.1016/j.eururo.2007.11.037 10.1007/s12325-019-01167-2 10.6004/jnccn.2018.0047 10.1056/NEJMra1703481 10.1001/jamaoncol.2017.2391 10.1056/NEJMoa1709684 10.1186/s12916-015-0455-8 10.1001/jamaoncol.2019.0393 10.1001/jamaoncol.2018.3923 10.3322/caac.21596 10.1007/s40266-019-00644-1 10.1200/JCO.2002.20.1.289 10.1200/JCO.1999.17.8.2530 10.1200/JCO.2008.21.4809 10.1016/S1470-2045(12)70559-4 10.1200/JCO.2017.35.6_suppl.492 10.1016/j.clgc.2016.12.005 10.1186/s12885-019-5716-z 10.1016/0959-8049(95)00664-8 10.1200/JCO.2001.19.4.1147 10.1016/j.ejca.2019.10.032
World Journal of Urology; Courcier J, De La Taille A et. al.

Feb 22nd, 2021 - Renal cell carcinoma (RCC) incidence has considerably increased during the last decades without any real impact on age-standardized mortality. It questions the relevance of aggressive treatments carrying potential side effects. Conservative manage...

Effect of improved systemic therapy on patient survival in metastatic non-clear-cell re...
https://doi.org/10.1111/iju.14523
International Journal of Urology : Official Journal of Th... Ishihara H, Tachibana H et. al.

Feb 22nd, 2021 - Effect of improved systemic therapy on patient survival in metastatic non-clear-cell renal cell carcinoma.|2021|Ishihara H,Tachibana H,Takagi T,Yoshida K,Kondo T,|

see more →

Guidelines  89 results

Rates and Predictors of Perioperative Complications in Cytoreductive Nephrectomy: Analysis of the Registry for Metastatic Renal Cell Carcinoma
https://www.sciencedirect.com/science/article/pii/S2588931120300547
European Urology Oncology; Roussel E

Aug 30th, 2020 - Cytoreductive nephrectomy (CN) plays an important role in the treatment of a subgroup of metastatic renal cell carcinoma (mRCC) patients.

Eric Jonasch, MD, on a Novel Therapy for Von Hippel-Lindau Disease–Associated RCC
https://ascopost.com/videos/asco20-virtual-scientific-program/eric-jonasch-on-a-novel-therapy-for-von-hippel-lindau-disease-associated-rcc/

May 31st, 2020 - Eric Jonasch, MD, of The University of Texas MD Anderson Cancer Center, discusses phase II study findings on the oral HIF-2α inhibitor known as MK-6482, which showed efficacy and tolerability in patients with Von Hippel-Lindau (VHL)–associated cle...

Cabozantinib Maintains Efficacy in Advanced RCC Irrespective of Prior Treatment
https://www.onclive.com/conference-coverage/asco-2020/cabozantinib-maintains-efficacy-in-advanced-rcc-irrespective-of-prior-treatment

May 30th, 2020 - Patients with advanced renal cell carcinoma (RCC) who were treated with the multikinase inhibitor cabozantinib (Cabometyx) following both immunotherapy (IO) and non-IO regimens demonstrated promising responses, suggesting the agent’s efficacy rega...

HIF2A Inhibitor for von Hippel-Lindau Disease–Associated Renal Cell Carcinoma
https://ascopost.com/news/may-2020/hif2a-inhibitor-for-von-hippel-lindau-disease-associated-renal-cell-carcinoma/

May 29th, 2020 - In an international trial, treatment with MK-6482, a small-molecule inhibitor of hypoxia-inducible factor (HIF)-2a, was well tolerated and resulted in clinical responses for patients with von Hippel-Lindau disease–associated renal cell carcinoma (...

Efficacy of Cabozantinib in Previously Treated RCC Is Consistent Irrespective of Prior Therapy
https://www.targetedonc.com/view/efficacy-of-cabozantinib-in-previously-treated-rcc-is-consistent-irrespective-of-prior-therapy

May 29th, 2020 - A pooled analysis of clinical trial data revealed that systemic therapy with cabozantinib (Cabometyx) in advanced renal cell carcinoma (RCC) induced reliable responses for patients regardless of whether or not they had received prior immunotherapy...

see more →

Drugs  55 results see all →

Clinicaltrials.gov  24,901 results

Loss of 9p21 regulatory hub promotes kidney cancer progression by upregulating HOXB13.
https://doi.org/10.1158/1541-7786.MCR-20-0705
Molecular Cancer Research : MCR; Baietti MF, Zhao P et. al.

Feb 23rd, 2021 - Loss of chromosome 9p21 is observed in one-thirds of clear cell renal cell carcinoma (ccRCC) and associated with poorer patient survival. Unexpectedly, 9p21 loss-of-heterozygosity (LOH) does not lead to decreased expression of the 9p21 tumor suppr...

Two Cases of Sporadic Eosinophilic Solid and Cystic Renal Cell Carcinoma in Manitoba Po...
https://doi.org/10.1177/1066896921993229
International Journal of Surgical Pathology; Mohaghegh Poor SM, Mathur S et. al.

Feb 22nd, 2021 - Two sporadic cases of eosinophilic solid and cystic renal cell carcinoma (ESC RCC), at our institution, are presented in this study to contribute to the growing literature on this novel renal neoplasm. The first patient was a 38-year-old female wi...

Comorbidity and frailty assessment in renal cell carcinoma patients.
https://doi.org/10.1007/s00345-021-03632-6 10.3322/caac.21492 10.1007/s00345-010-0555-1 10.14740/wjon1279 10.1016/s0022-5347(17)68620-8 10.1016/j.eururo.2011.03.030 10.1016/j.annonc.2020.11.016 10.1016/S0140-6736(19)30723-8 10.1016/S1470-2045(20)30436-8 10.1016/j.annonc.2020.04.010 10.1056/NEJMoa1712126 10.1016/j.eururo.2019.02.011 10.1016/S0022-5347(05)00148-5 10.1097/01.ju.0000095475.12515.5e 10.1093/jnci/djj362 10.1002/cncr.25184 10.1002/cncr.26369 10.1016/j.eururo.2020.06.053 10.1016/j.juro.2014.03.038 10.1016/j.euf.2017.11.005 10.1016/j.juro.2009.12.101 10.2147/RRU.S220221 10.1016/j.eururo.2016.08.060 10.1016/j.eururo.2006.11.013 10.1016/j.urology.2014.01.050 10.1093/gerona/56.3.m146 10.1097/HJH.0000000000001286 10.1097/MOU.0000000000000454 10.1016/j.urolonc.2018.12.008 10.18632/oncotarget.3749 10.1002/ijc.28093 10.1016/j.eururo.2018.08.036 10.1016/1047-2797(91)90005-W 10.1093/annonc/mdr587 10.1200/JCO.2013.54.8347 10.1200/JCO.2013.51.1345 10.1371/journal.pone.0115060 10.1016/0021-9681(87)90171-8 10.1016/0895-4356(94)90129-5 10.1007/s00432-019-03042-7 10.1200/JCO.2009.22.4816 10.1016/j.cell.2010.01.025 10.2147/CMAR.S208839 10.1093/annonc/mdw328 10.1016/S1470-2045(16)30196-6 10.1016/j.urolonc.2007.10.017 10.1200/JCO.2019.37.15_suppl.4516 10.21037/atm.2019.01.08 10.1016/j.urolonc.2018.08.018 10.1016/j.eururo.2019.05.022 10.1016/j.eururo.2016.09.034 10.1016/j.eururo.2015.01.005 10.1016/annoncannonc325 10.1056/NEJMoa1816714 10.1056/NEJMoa1816047 10.1016/S0140-6736(19)30723-8 10.1016/j.eururo.2007.11.037 10.1007/s12325-019-01167-2 10.6004/jnccn.2018.0047 10.1056/NEJMra1703481 10.1001/jamaoncol.2017.2391 10.1056/NEJMoa1709684 10.1186/s12916-015-0455-8 10.1001/jamaoncol.2019.0393 10.1001/jamaoncol.2018.3923 10.3322/caac.21596 10.1007/s40266-019-00644-1 10.1200/JCO.2002.20.1.289 10.1200/JCO.1999.17.8.2530 10.1200/JCO.2008.21.4809 10.1016/S1470-2045(12)70559-4 10.1200/JCO.2017.35.6_suppl.492 10.1016/j.clgc.2016.12.005 10.1186/s12885-019-5716-z 10.1016/0959-8049(95)00664-8 10.1200/JCO.2001.19.4.1147 10.1016/j.ejca.2019.10.032
World Journal of Urology; Courcier J, De La Taille A et. al.

Feb 22nd, 2021 - Renal cell carcinoma (RCC) incidence has considerably increased during the last decades without any real impact on age-standardized mortality. It questions the relevance of aggressive treatments carrying potential side effects. Conservative manage...

Effect of improved systemic therapy on patient survival in metastatic non-clear-cell re...
https://doi.org/10.1111/iju.14523
International Journal of Urology : Official Journal of Th... Ishihara H, Tachibana H et. al.

Feb 22nd, 2021 - Effect of improved systemic therapy on patient survival in metastatic non-clear-cell renal cell carcinoma.|2021|Ishihara H,Tachibana H,Takagi T,Yoshida K,Kondo T,|

see more →

News  1,089 results

Combo Shows 'Impressive' Survival Results in First-Line RCC
https://www.medscape.com/viewarticle/946025

Feb 17th, 2021 - The combination of lenvatinib and pembrolizumab outperforms sunitinib as first-line therapy for advanced clear-cell renal cell carcinoma (RCC), based on findings of the CLEAR trial. Results from the phase 3 trial were reported at the 2021 Genitour...

Cabozantinib Could Be New Standard for Papillary RCC
https://www.medscape.com/viewarticle/945955

Feb 16th, 2021 - When treating metastatic papillary renal cell carcinoma (RCC), cabozantinib outperforms the current standard of care, according to results from the Southwest Oncology Group (SWOG) 1500 trial. Compared with the VEGFR-2 inhibitor sunitinib, the MET ...

Which Patients With Kidney Cancer Are Likely to Respond to ICI?
https://www.medscape.com/viewarticle/945382

Feb 4th, 2021 - Several factors associated with a diminished response to immune checkpoint inhibitor (ICI) drugs among patients with metastatic clear cell renal cell carcinoma (ccRCC) have been identified. They include the patient being aged 75 years or older, be...

ACE2-Generated Small Peptide Shows Promise in Clear Cell Kidney Cancer
https://www.medscape.com/viewarticle/944811

Jan 27th, 2021 - NEW YORK (Reuters Health) - Angiotensin-(1-7), a small peptide generated by angiotensin-converting enzyme 2 (ACE2), shows promise in combination with a programmed death-ligand 1 (PD-L1) pathway inhibitor and a vascular endothelial growth factor re...

Predicting Complications of Cytoreductive Nephrectomy in mRCC
https://www.medscape.com/viewarticle/938091

Sep 24th, 2020 - Patients with higher intraoperative blood loss and those treated at lower-volume surgical centers had a greater risk of high-grade complications after undergoing cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC), according ...

see more →

Patient Education  5 results see all →